MaaT Pharma receives negative opinion for MaaT013 treatment

The CHMP issues a negative trend vote for MaaT013 (Xervyteg®) during its reassessment.

Published 3h1 sourceupdated 2h

≈ 16sSpeed

The fact

This treatment is developed for specific hematological indications.

MaaT Pharma will need to revise its regulatory strategy before resubmission.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on September 15, 2026